Lupus Nephritis: Novel Treatments and Diagnostic Approaches

被引:0
|
作者
Jain N.G. [1 ,3 ]
Hunt E.A.K. [1 ,3 ]
Paul E. [2 ,3 ]
Somers M.J.G. [1 ,3 ]
机构
[1] Division of Nephrology, Boston Children’s Hospital, 300 Longwood Avenue, Boston
[2] Division of Pediatric Nephrology, MassGeneral Hospital for Children, Boston, MA
[3] Department of Pediatrics, Harvard Medical School, Boston, MA
关键词
Belimumab; Cyclosporine (CSA); IVCY; Lupus nephritis; MMF; Rituximab; Systemic lupus erythematous (SLE);
D O I
10.1007/s40124-012-0005-1
中图分类号
学科分类号
摘要
Over the last decade, therapy for lupus nephritis in children has begun to shift from the provision of long-term steroids and intravenous cyclophosphamide to regimens with limited or no cyclophosphamide, lower steroid burdens, and increased reliance on oral mycophenolate mofetil. As the molecular immunology underlying the pathophysiology of lupus is further discerned, more targeted therapies, including the use of monoclonal antibodies against immune cells or cell signaling factors, may come to play a larger role in the treatment of pediatric lupus. Similarly, as experience with autologous stem cell transplantation for therapy-resistant disease is gained in adults, its potential applicability to such situations in children may be clarified. Over the next few decades, children with lupus will benefit as well from the identification of new biomarkers that are both sensitive and specific to disease activity, allowing clinicians to more readily assess response to therapy and diagnose disease flare. © 2012, Springer Science + Business Media New York.
引用
收藏
页码:41 / 51
页数:10
相关论文
共 50 条
  • [1] Novel approaches in the treatment of lupus nephritis
    Illei, GG
    Klippel, JH
    LUPUS, 1998, 7 (09) : 644 - 648
  • [2] Novel approaches in the treatment of lupus nephritis
    Illei, GG
    Czirják, L
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2001, 10 (06) : 1117 - 1130
  • [3] Update on Novel Blood-Based Biomarkers for Lupus Nephritis Beyond Diagnostic Approaches
    Maravillas-Montero, Jose L.
    Reyes-Huerta, Raul F.
    REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION, 2022, 74 (05): : 227 - 231
  • [4] Serum tsRNA as a novel molecular diagnostic biomarker for lupus nephritis
    Zhang, Xiaoshan
    Yang, Ping
    Khan, Adeel
    Xu, Dongjie
    Chen, Shanshan
    Zhai, Junbin
    Zhang, Bin
    Xiong, Tao
    Wang, Yanbo
    Li, Zhiyang
    CLINICAL AND TRANSLATIONAL MEDICINE, 2022, 12 (05):
  • [5] New and Emerging Treatments for Lupus Nephritis
    Canetta, Pietro A. A.
    Appel, Gerald B.
    DIALYSIS & TRANSPLANTATION, 2011, 40 (02) : 67 - 71
  • [6] Lupus nephritis: An update on treatments and pathogenesis
    Yap, Desmond Y. H.
    Yung, Susan
    Chan, Tak Mao
    NEPHROLOGY, 2018, 23 : 80 - 83
  • [7] Are new treatments for lupus nephritis on the horizon?
    Ginzler, Ellen M.
    KIDNEY INTERNATIONAL, 2021, 99 (02) : 298 - 300
  • [8] Novel pebtide and gene vaccination approaches to modulate lupus nephritis.
    Singh, RR
    Yang, JQ
    Fan, GC
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 369A - 370A
  • [9] Lupus nephritis: a review of the current pharmacological treatments
    Mercadal, L
    Deray, G
    EXPERT OPINION ON PHARMACOTHERAPY, 2004, 5 (11) : 2263 - 2277
  • [10] Novel therapies of lupus nephritis
    Schieppati, Arrigo
    Remuzzi, Giuseppe
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2008, 17 (02): : 156 - 161